Allogeneic hematopoietic stem cell transplantation in Fanconi anemia

The European Group for Blood and Marrow Transplantation experience

Régis Peffault De Latour, Raphael Porcher, Jean Hugues Dalle, Mahmoud Aljurf, Elisabeth T. Korthof, Johanna Svahn, Roelof Willemze, Cristina Barrenetxea, Valerie Mialou, Jean Soulier, Mouhab Ayas, Rosi Oneto, Andrea Bacigalupo, Judith C W Marsh, Christina Peters, Gerard Socie, Carlo Dufour

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Although allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative treatment for patients with Fanconi anemia (FA), published series mostly refer to single-center experience with limited numbers of patients. We analyzed results in 795 patients with FA who underwent first HSCT between May 1972 and January 2010. With a 6-year median follow-up, overall survival was 49% at 20 years (95% confidence interval, 38-65 years). Better outcome was observed for patients transplanted before the age of 10 years, before clonal evolution (ie, myelodysplastic syndrome or acute myeloid leukemia), from a matched family donor, after a conditioning regimen without irradiation, the latter including fludarabine. Chronic graft-versus-host disease and secondary malignancy were deleterious when considered as time-dependent covariates. Age more than 10 years at time of HSCT, clonal evolution as an indication for transplantation, peripheral blood as source of stem cells, and chronic graft-versus-host disease were found to be independently associated with the risk for secondary malignancy. Changes in transplant protocols have significantly improved the outcome of patients with FA, who should be transplanted at a young age, with bone marrow as the source of stem cells.

Original languageEnglish
Pages (from-to)4279-4286
Number of pages8
JournalBlood
Volume122
Issue number26
DOIs
Publication statusPublished - Dec 19 2013

Fingerprint

Fanconi Anemia
Hematopoietic Stem Cell Transplantation
Stem cells
Clonal Evolution
Graft vs Host Disease
Grafts
Stem Cells
Transplants
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Neoplasms
Bone
Blood
Transplantation
Bone Marrow
Tissue Donors
Irradiation
Confidence Intervals
Survival

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Allogeneic hematopoietic stem cell transplantation in Fanconi anemia : The European Group for Blood and Marrow Transplantation experience. / De Latour, Régis Peffault; Porcher, Raphael; Dalle, Jean Hugues; Aljurf, Mahmoud; Korthof, Elisabeth T.; Svahn, Johanna; Willemze, Roelof; Barrenetxea, Cristina; Mialou, Valerie; Soulier, Jean; Ayas, Mouhab; Oneto, Rosi; Bacigalupo, Andrea; Marsh, Judith C W; Peters, Christina; Socie, Gerard; Dufour, Carlo.

In: Blood, Vol. 122, No. 26, 19.12.2013, p. 4279-4286.

Research output: Contribution to journalArticle

De Latour, RP, Porcher, R, Dalle, JH, Aljurf, M, Korthof, ET, Svahn, J, Willemze, R, Barrenetxea, C, Mialou, V, Soulier, J, Ayas, M, Oneto, R, Bacigalupo, A, Marsh, JCW, Peters, C, Socie, G & Dufour, C 2013, 'Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: The European Group for Blood and Marrow Transplantation experience', Blood, vol. 122, no. 26, pp. 4279-4286. https://doi.org/10.1182/blood-2013-01-479733
De Latour, Régis Peffault ; Porcher, Raphael ; Dalle, Jean Hugues ; Aljurf, Mahmoud ; Korthof, Elisabeth T. ; Svahn, Johanna ; Willemze, Roelof ; Barrenetxea, Cristina ; Mialou, Valerie ; Soulier, Jean ; Ayas, Mouhab ; Oneto, Rosi ; Bacigalupo, Andrea ; Marsh, Judith C W ; Peters, Christina ; Socie, Gerard ; Dufour, Carlo. / Allogeneic hematopoietic stem cell transplantation in Fanconi anemia : The European Group for Blood and Marrow Transplantation experience. In: Blood. 2013 ; Vol. 122, No. 26. pp. 4279-4286.
@article{8afc5cbe61e94779b137ae6781fb2dd5,
title = "Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: The European Group for Blood and Marrow Transplantation experience",
abstract = "Although allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative treatment for patients with Fanconi anemia (FA), published series mostly refer to single-center experience with limited numbers of patients. We analyzed results in 795 patients with FA who underwent first HSCT between May 1972 and January 2010. With a 6-year median follow-up, overall survival was 49{\%} at 20 years (95{\%} confidence interval, 38-65 years). Better outcome was observed for patients transplanted before the age of 10 years, before clonal evolution (ie, myelodysplastic syndrome or acute myeloid leukemia), from a matched family donor, after a conditioning regimen without irradiation, the latter including fludarabine. Chronic graft-versus-host disease and secondary malignancy were deleterious when considered as time-dependent covariates. Age more than 10 years at time of HSCT, clonal evolution as an indication for transplantation, peripheral blood as source of stem cells, and chronic graft-versus-host disease were found to be independently associated with the risk for secondary malignancy. Changes in transplant protocols have significantly improved the outcome of patients with FA, who should be transplanted at a young age, with bone marrow as the source of stem cells.",
author = "{De Latour}, {R{\'e}gis Peffault} and Raphael Porcher and Dalle, {Jean Hugues} and Mahmoud Aljurf and Korthof, {Elisabeth T.} and Johanna Svahn and Roelof Willemze and Cristina Barrenetxea and Valerie Mialou and Jean Soulier and Mouhab Ayas and Rosi Oneto and Andrea Bacigalupo and Marsh, {Judith C W} and Christina Peters and Gerard Socie and Carlo Dufour",
year = "2013",
month = "12",
day = "19",
doi = "10.1182/blood-2013-01-479733",
language = "English",
volume = "122",
pages = "4279--4286",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "26",

}

TY - JOUR

T1 - Allogeneic hematopoietic stem cell transplantation in Fanconi anemia

T2 - The European Group for Blood and Marrow Transplantation experience

AU - De Latour, Régis Peffault

AU - Porcher, Raphael

AU - Dalle, Jean Hugues

AU - Aljurf, Mahmoud

AU - Korthof, Elisabeth T.

AU - Svahn, Johanna

AU - Willemze, Roelof

AU - Barrenetxea, Cristina

AU - Mialou, Valerie

AU - Soulier, Jean

AU - Ayas, Mouhab

AU - Oneto, Rosi

AU - Bacigalupo, Andrea

AU - Marsh, Judith C W

AU - Peters, Christina

AU - Socie, Gerard

AU - Dufour, Carlo

PY - 2013/12/19

Y1 - 2013/12/19

N2 - Although allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative treatment for patients with Fanconi anemia (FA), published series mostly refer to single-center experience with limited numbers of patients. We analyzed results in 795 patients with FA who underwent first HSCT between May 1972 and January 2010. With a 6-year median follow-up, overall survival was 49% at 20 years (95% confidence interval, 38-65 years). Better outcome was observed for patients transplanted before the age of 10 years, before clonal evolution (ie, myelodysplastic syndrome or acute myeloid leukemia), from a matched family donor, after a conditioning regimen without irradiation, the latter including fludarabine. Chronic graft-versus-host disease and secondary malignancy were deleterious when considered as time-dependent covariates. Age more than 10 years at time of HSCT, clonal evolution as an indication for transplantation, peripheral blood as source of stem cells, and chronic graft-versus-host disease were found to be independently associated with the risk for secondary malignancy. Changes in transplant protocols have significantly improved the outcome of patients with FA, who should be transplanted at a young age, with bone marrow as the source of stem cells.

AB - Although allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative treatment for patients with Fanconi anemia (FA), published series mostly refer to single-center experience with limited numbers of patients. We analyzed results in 795 patients with FA who underwent first HSCT between May 1972 and January 2010. With a 6-year median follow-up, overall survival was 49% at 20 years (95% confidence interval, 38-65 years). Better outcome was observed for patients transplanted before the age of 10 years, before clonal evolution (ie, myelodysplastic syndrome or acute myeloid leukemia), from a matched family donor, after a conditioning regimen without irradiation, the latter including fludarabine. Chronic graft-versus-host disease and secondary malignancy were deleterious when considered as time-dependent covariates. Age more than 10 years at time of HSCT, clonal evolution as an indication for transplantation, peripheral blood as source of stem cells, and chronic graft-versus-host disease were found to be independently associated with the risk for secondary malignancy. Changes in transplant protocols have significantly improved the outcome of patients with FA, who should be transplanted at a young age, with bone marrow as the source of stem cells.

UR - http://www.scopus.com/inward/record.url?scp=84891061185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891061185&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-01-479733

DO - 10.1182/blood-2013-01-479733

M3 - Article

VL - 122

SP - 4279

EP - 4286

JO - Blood

JF - Blood

SN - 0006-4971

IS - 26

ER -